Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:30 a.m. PT.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl . An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics® . Biclonics® , which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is expected to soon be evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target and is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus' website, www.merus.nl .
+1 646 368 8014
+1 973 361 1546
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Inspiration Mining Corporation20.2.2018 21:37 | pressemeddelelse
Inspiration Mining to File a Complaint with OSC Against Stockwatch
Aurora Solar Technologies Inc.20.2.2018 21:09 | pressemeddelelse
Aurora Releases Third Quarter Results
Bermuda Business Development Agency (BDA)20.2.2018 16:38 | pressemeddelelse
Bermuda Principles event merges science and business
Elite Capital & Co. Limited20.2.2018 15:43 | pressemeddelelse
Elite Capital & Co. awarded Infrastructure Project Finance Provider 2018 by New European Economy
Corel20.2.2018 15:28 | pressemeddelelse
New MindManager 11 for Mac: Visually Capture, Organize, and Share Information to Drive Project and Business Success
Cisco20.2.2018 14:02 | pressemeddelelse
Cisco Leadership In Automation Continues With New Network Automation Portfolio for Service Providers
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum